Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3756639 | 0.84 | LMNA (0.44) | LMNASLC34A1SMN1; SMN2POLBPDE4A | |
| SCHEMBL23138363 | 0.82 | NOTUM (0.45) | LMNAPOLBCRHR1L3MBTL1ALDH1A1 | |
| SCHEMBL6188814 | 0.82 | MAPT (0.52) | LMNASMN1; SMN2POLBFAAHTDP1 | |
| SCHEMBL3044615 | 0.81 | CRHR1 (0.46) | LMNAPOLBCRHR1L3MBTL1MAPT | |
| SCHEMBL24757774 | 0.81 | LMNA (0.45) | LMNAPOLBCRHR1TDP1RAB9A | |
| SCHEMBL2931607 | 0.79 | LMNA (0.47) | LMNASMN1; SMN2POLBFAAHTDP1 | |
| SCHEMBL20944010 | 0.79 | LMNA (0.40) | LMNASLC34A1SMN1; SMN2POLBPDE4A | |
| SCHEMBL18003584 | 0.79 | SMN1; SMN2 (0.57) | LMNASLC34A1SMN1; SMN2POLBFAAH | |
| SCHEMBL18718147 | 0.79 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2POLBTDP1RAB9A | |
| SCHEMBL1198071 | 0.78 | LMNA (0.58) | LMNASMN1; SMN2POLBTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492212-B2 | Substituted pyrazolecarboxamides as sting activators | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-12-09 | — | — | US | disclosed |
| CN-114981273-B | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国科学院上海药物研究所 | 2024-03-01 | — | — | CN | disclosed |
| CN-112351778-B | Fused tricyclic heterocycles and therapeutic uses thereof | 江苏恒瑞医药股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| US-20220389025-A1 | HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-12-08 | — | — | US | disclosed |
| US-20220389025-A1 | HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-12-08 | — | — | US | disclosed |
| CN-112521371-B | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国药科大学 | 2022-11-25 | — | — | CN | disclosed |
| CN-114981273-A | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method and application thereof | 中国科学院上海药物研究所 | 2022-08-30 | — | — | CN | disclosed |
| EP-4032890-A1 | HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-07-27 | — | — | EP | disclosed |
| US-20210300944-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
| WO-2021052501-A1 | HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2021-03-25 | — | — | WO | disclosed |
| CN-112351778-A | Fused tricyclic heterocycles and therapeutic uses thereof | 江苏恒瑞医药股份有限公司 | 2021-02-09 | — | — | CN | disclosed |
| US-5126362-A | Substituted pyrazoylacetamides | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1992-06-30 | — | — | US | disclosed |
| EP-0361362-A1 | Oxime derivative and fungicide for agricultural and horticultural use | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | STING1, CGAS, MAVS | LMNA 139/4885SLC34A1 2394/4885SMN1; SMN2 1186/4885 |
| US-20220389025-A1 | HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | STING1, CGAS, MYD88 | LMNA 3488/4885SLC34A1 554/4885SMN1; SMN2 2965/4885 |
| US-12492212-B2 | Substituted pyrazolecarboxamides as sting activators | STING1, CGAS, TBK1 | LMNA 2569/4885SLC34A1 946/4885SMN1; SMN2 3907/4885 |
| US-20210300944-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | STING1, CGAS, MAVS | LMNA 139/4885SLC34A1 2394/4885SMN1; SMN2 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.